Last updated: September 7, 2026
Clofarabine is a narrow-market oncology drug approved in the United States as Clolar for pediatric patients aged 1 to 21 years with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. Its commercial profile is defined by orphan-drug economics, limited patient volume, hospital-based administration, competition from newer salvage therapies, and the absence of separately reported product revenue. The product remains clinically relevant in selected pediatric leukemia cases, but it is not a major growth asset for Sanofi or the broader oncology market. [1]
What is clofarabine and which patients does it treat?
Clofarabine is a purine nucleoside analog that inhibits ribonucleotide reductase and DNA polymerase and induces apoptosis in leukemic cells. The FDA approved clofarabine injection on December 28, 2006, under the brand name Clolar. The approved indication covers pediatric patients aged 1 to 21 years with relapsed or refractory acute lymphoblastic leukemia after at least two prior treatment regimens. [1]
The drug is administered intravenously in a hospital or specialist oncology setting. Its use is concentrated in pediatric hematology-oncology centers and transplant referral networks.
FDA-approved indication
| Attribute |
Clofarabine status |
| Active ingredient |
Clofarabine |
| U.S. brand |
Clolar |
| FDA applicant at approval |
Genzyme Corporation |
| U.S. approval date |
December 28, 2006 |
| Dosage form |
Intravenous injection, 1 mg/mL |
| Approved population |
Patients aged 1 to 21 years |
| Disease |
Relapsed or refractory acute lymphoblastic leukemia |
| Prior therapy requirement |
At least two prior regimens |
| Regulatory designation |
Orphan drug |
| Administration |
Intravenous, generally over five consecutive days |
The label carries serious warnings relating to hepatotoxicity, renal toxicity, capillary leak syndrome, systemic inflammatory response, and other severe adverse reactions. These risks constrain use outside specialist centers and increase monitoring costs. [1]
How large is the clofarabine market?
Clofarabine addresses a small, highly specialized market. Its commercial demand is linked to the number of pediatric patients who relapse after multiple lines of therapy and remain candidates for intensive salvage treatment.
The market is constrained by several factors:
- Pediatric acute lymphoblastic leukemia is relatively uncommon compared with adult leukemia.
- Most patients achieve durable remission with frontline therapy.
- Relapsed patients may proceed to blinatumomab, inotuzumab ozogamicin, CAR-T therapy, reinduction chemotherapy, or hematopoietic stem-cell transplantation.
- Clofarabine is administered intravenously and generally requires inpatient or closely monitored treatment.
- The approved indication is restricted to a heavily pretreated population.
- The drug is used primarily as a salvage or bridging regimen rather than as a broad maintenance therapy.
The addressable patient population is therefore measured in thousands globally, not hundreds of thousands. U.S. demand is likely concentrated in a few hundred to low-thousands of treatment courses annually, depending on availability, clinical practice, and use in combination regimens. No public source establishes a current global patient count or audited market value.
What is the financial trajectory for clofarabine?
Standalone clofarabine revenue is not disclosed in Sanofi’s public financial reporting. Sanofi reports oncology performance at a broader portfolio level and does not identify Clolar sales as a separate material product line. This prevents a reliable calculation of annual product revenue, operating margin, or current market share from public filings. [2]
The commercial trajectory has followed four identifiable phases.
Commercial development timeline
| Period |
Event |
Financial or market effect |
| Early 2000s |
Development and orphan positioning |
Created a focused pediatric leukemia opportunity |
| 2006 |
FDA approval of Clolar |
Enabled U.S. commercial sales in relapsed/refractory pediatric ALL |
| 2007 |
Genzyme acquisition of Bioenvision |
Consolidated clofarabine-related commercial rights within Genzyme |
| 2011 |
Sanofi acquisition of Genzyme |
Made Clolar part of Sanofi’s specialty-care portfolio |
| 2010s |
Expansion of competing salvage therapies |
Reduced strategic growth potential |
| Late 2010s onward |
Mature product and limited disclosed investment |
Market shifted toward supply continuity rather than expansion |
Genzyme acquired Bioenvision in 2007 in a transaction valued at approximately $345 million. The acquisition gave Genzyme control of Bioenvision’s clofarabine business and related development assets. Sanofi subsequently acquired Genzyme in 2011. [3,4]
The acquisition history indicates that clofarabine had strategic value as an orphan oncology product, but it does not establish that the drug generated material revenue for Sanofi. Its economic importance is better characterized as a niche specialty product with limited revenue concentration and modest growth potential.
Which companies manufacture or commercialize clofarabine?
Clolar was developed and commercialized through Bioenvision and Genzyme, with Sanofi becoming the ultimate corporate owner after its acquisition of Genzyme. Publicly available product information identifies Genzyme Corporation as the original U.S. applicant. [1,3,4]
The commercial landscape is less transparent than for large primary-care products because:
- The product is sold through institutional oncology channels.
- Manufacturer revenue is not separately disclosed.
- Supply may be managed through specialty distributors and hospital procurement systems.
- Product availability can vary by market and over time.
- Use can occur under institutional protocols or combination regimens that are not captured by simple prescription-volume metrics.
Potential competition comes from other manufacturers of salvage therapies rather than only from direct clofarabine substitutes. Relevant competitors include manufacturers of blinatumomab, inotuzumab ozogamicin, CAR-T therapies, and conventional reinduction chemotherapy.
How does clofarabine compare with competing leukemia treatments?
Clofarabine’s commercial position has weakened as targeted and cellular therapies have expanded.
| Therapy |
Primary role in relapsed B-cell ALL |
Commercial effect on clofarabine |
| Clofarabine |
Cytotoxic salvage or combination therapy |
Established but narrow role |
| Blinatumomab |
T-cell engager for relapsed or refractory B-cell precursor ALL |
Directly competes for salvage treatment |
| Inotuzumab ozogamicin |
Antibody-drug conjugate for relapsed or refractory B-cell precursor ALL |
Reduces use of conventional chemotherapy in eligible patients |
| CAR-T therapy |
Cellular therapy for selected relapsed or refractory B-cell ALL |
Competes for high-value later-line patients |
| Conventional reinduction regimens |
Cytotoxic salvage treatment |
Remains a lower-cost alternative in some centers |
| Stem-cell transplantation |
Consolidation after remission |
Often follows, rather than directly replaces, salvage therapy |
Blinatumomab and inotuzumab provide more disease-specific mechanisms and have become important options in relapsed B-cell ALL. CAR-T therapy has further shifted treatment algorithms for eligible patients. Clofarabine retains utility when a center needs a cytotoxic induction or bridging regimen, when targeted therapy is unsuitable, or when a combination protocol calls for it.
Its value proposition is therefore clinical flexibility in a constrained setting rather than premium-market expansion.
What is the Orange Book status of clofarabine?
The FDA approved clofarabine under NDA 021673. The original product was listed as Clolar injection. [5]
The commercial significance of Orange Book protection is limited compared with a newly launched specialty drug. Any relevant U.S. patent protection associated with the original clofarabine product has aged substantially since the 2006 approval. The product’s market risk is therefore more closely tied to regulatory filing status, manufacturing economics, supply reliability, and the small size of the patient population than to a strong, newly expiring composition-of-matter patent.
A current Orange Book review should distinguish among:
- Active patents listed for the NDA.
- Expired or delisted patents.
- Pediatric exclusivity attached to the original approval.
- Any approved supplements covering new formulations or uses.
- Actual commercial availability of an authorized generic or other ANDA product.
No widely reported, commercially significant Paragraph IV campaign has shaped the clofarabine market in the manner seen with major oncology blockbusters.
When did clofarabine lose exclusivity?
Clofarabine received orphan-drug exclusivity in the United States. The standard orphan exclusivity period is seven years from approval, subject to statutory conditions. The December 2006 approval therefore placed the core orphan exclusivity period in the early 2010s. Pediatric exclusivity could extend relevant protections by six months if the statutory requirements were satisfied. [1,6]
The commercial protection timeline can be summarized as follows:
| Protection type |
Approximate status |
| FDA approval |
December 2006 |
| Seven-year orphan exclusivity |
Expired around late 2013, subject to statutory calculation |
| Pediatric exclusivity |
Could add six months if granted |
| New chemical entity exclusivity |
Not the principal commercial protection cited for Clolar |
| Patent estate |
Historic protections have matured; current blocking strength is limited |
| Current exclusivity value |
Primarily clinical familiarity, specialist use, and supply position |
Expiration of exclusivity did not create a large generic market because the addressable population is small and intravenous oncology manufacturing is commercially demanding.
Are there Paragraph IV challenges or generic clofarabine risks?
The principal generic-entry risk is moderate from a legal perspective but limited in commercial impact.
A generic applicant would need to demonstrate bioequivalence and satisfy requirements applicable to an injectable oncology product. The main barriers are commercial:
- Small annual unit demand.
- High quality-control and sterile manufacturing requirements.
- Limited hospital purchasing volume.
- Potentially low return on regulatory investment.
- Competition from other salvage regimens.
- Need for reliable supply to specialized treatment centers.
Because the product is an injectable solution rather than a complex device or long-acting delivery system, technical formulation barriers are lower than for liposomal, depot, inhaled, or biologic products. Manufacturing still requires validated sterile processes, active pharmaceutical ingredient control, and stability data.
No major public litigation campaign involving a Paragraph IV challenge is broadly associated with clofarabine. The absence of prominent litigation suggests that the expected value of challenging the product was limited relative to the cost of filing and commercializing a generic.
What formulation and manufacturing protections matter?
Clofarabine is supplied as a sterile intravenous injection. The commercially relevant protection profile is therefore linked to:
- Active pharmaceutical ingredient synthesis.
- Sterile injectable manufacturing.
- Solubility and stability control.
- Container-closure compatibility.
- Storage and handling requirements.
- Label-prescribed infusion procedures.
- Quality systems for low-volume oncology injectables.
Unlike biologics, clofarabine does not create biosimilar substitution issues. It is a small-molecule drug and would be subject to the abbreviated new drug application pathway if a generic applicant pursued approval.
The manufacturing barrier is meaningful but not insurmountable. The larger obstacle is market economics. A generic manufacturer could face limited volume, price pressure, and the risk of intermittent shortages if only one or two suppliers enter the market.
What is the FDA regulatory status of clofarabine?
Clolar has FDA approval for its pediatric relapsed or refractory ALL indication. The label remains clinically important because it defines the approved population and includes detailed warnings on potentially fatal toxicity. [1]
The drug does not have the regulatory breadth of newer leukemia products. Its label does not cover the full range of adult acute lymphoblastic leukemia, frontline therapy, or all relapsed disease subtypes. Off-label use may occur in institutional protocols, but off-label demand is difficult to quantify and does not create the same commercial predictability as a broad FDA indication.
Regulatory upside is limited unless a sponsor pursues a new indication, combination regimen, or pediatric development program. Given the small market and competing therapies, a major label-expansion program would require a clear clinical and reimbursement rationale.
What patent litigation and settlement agreements affect clofarabine?
No prominent, market-defining patent litigation or settlement agreement is broadly associated with Clolar. The product does not have the litigation profile of high-revenue drugs with multiple ANDA filers and large settlement payments.
The absence of major litigation has two interpretations:
- Patent barriers were not sufficiently valuable to support extensive challenger activity.
- The market was too small to justify aggressive generic litigation even after exclusivity expired.
There is no widely reported authorized-generic settlement structure that materially changed the clofarabine market. Commercial competition is more likely to arise through product availability, hospital contracting, and clinical protocol selection than through a patent settlement.
What revenue exposure does clofarabine create for Sanofi?
Clofarabine represents limited direct revenue exposure for Sanofi compared with the company’s major vaccines, immunology products, rare-disease therapies, and oncology brands.
Its financial characteristics are:
- Low disclosed revenue concentration.
- Small and specialized customer base.
- Limited growth from new patient acquisition.
- Exposure to hospital purchasing and reimbursement.
- Potential margin pressure from low-volume sterile manufacturing.
- Limited downside from generic entry because the product is not a major reported revenue driver.
For Sanofi, the product’s strategic value is likely measured through portfolio completeness, patient access, and specialty-oncology presence rather than material contribution to consolidated sales.
What generic launch scenarios exist for clofarabine?
Scenario 1: No meaningful generic entry
This is the most commercially plausible outcome if demand remains small and incumbent supply remains adequate. The originator or an established supplier retains the market through availability, physician familiarity, and procurement relationships.
Scenario 2: One generic entrant
A single generic could reduce net prices while preserving supply continuity. The entrant would likely target hospitals and specialty distributors rather than retail pharmacies. Market share could grow gradually because treatment centers often prioritize reliable supply for low-volume injectable oncology products.
Scenario 3: Multiple generic entrants
Several entrants could produce sharp price compression and unstable supply economics. The market could become vulnerable to shortages if manufacturers exit after prices fall below sustainable production levels.
Scenario 4: Clinical displacement without generic erosion
Clofarabine could lose volume even without generic competition if clinicians increasingly use blinatumomab, inotuzumab, CAR-T therapy, or other salvage approaches. This is the most important long-term commercial risk.
How strong is the clofarabine patent estate?
The patent estate is commercially weak relative to newer oncology products. The core product was approved in 2006, orphan exclusivity expired in the early 2010s, and historic patent protections have had extensive time to mature.
Patent strength should be assessed as limited for three reasons:
- The principal product has been commercially available for nearly two decades.
- No major current litigation campaign has established a durable exclusionary position.
- The primary market defenses are manufacturing, supply reliability, specialist adoption, and limited market size.
The estate may still contain jurisdiction-specific claims or historical formulation and process claims, but these are unlikely to provide broad, long-duration exclusivity comparable to a recently launched drug.
What is the geographic coverage of clofarabine?
The United States remains the clearest reference market because of the FDA-approved Clolar label. European commercialization has been more constrained, with the product’s European authorization and commercial status subject to withdrawal and supply changes over time. International availability depends on local registrations, procurement arrangements, and the presence of alternative leukemia therapies.
Geographic expansion is difficult because the drug requires specialist administration and the eligible patient population is small in every major market. Emerging-market opportunity is limited by diagnostic capacity, pediatric oncology infrastructure, reimbursement, and access to competing therapies.
Key Takeaways
- Clofarabine is an orphan injectable oncology drug approved for pediatric relapsed or refractory ALL.
- Its addressable market is small and concentrated in specialist pediatric leukemia centers.
- Sanofi does not separately disclose Clolar revenue, so product-level financial estimates cannot be reliably calculated from public filings.
- Genzyme acquired Bioenvision in 2007, and Sanofi acquired Genzyme in 2011.
- U.S. orphan exclusivity expired around the early 2010s, with possible pediatric extension.
- No major Paragraph IV litigation or patent settlement has defined the product’s market.
- Generic entry is legally feasible but commercially constrained by low volume and sterile manufacturing requirements.
- The most significant competitive risk comes from blinatumomab, inotuzumab, CAR-T therapy, and transplant-based treatment pathways.
- Clofarabine’s future is more dependent on clinical protocol use and product availability than on patent exclusivity.
- The product is unlikely to become a significant growth asset without a new indication, combination strategy, or major change in relapsed ALL treatment practice.
FAQs About Clofarabine Market and Exclusivity
Is clofarabine still commercially available in the United States?
Clolar has an FDA-approved product record, but actual availability can depend on current manufacturer distribution, hospital procurement, and supply conditions. FDA approval does not guarantee continuous commercial supply.
Is clofarabine a chemotherapy drug or a targeted therapy?
Clofarabine is a conventional antimetabolite chemotherapy and purine nucleoside analog. It is not a monoclonal antibody, antibody-drug conjugate, CAR-T therapy, or other biologic treatment.
Does clofarabine have biosimilar competition?
No. Clofarabine is a small-molecule drug, so the relevant competitive pathway is generic competition through an ANDA rather than biosimilar competition under the Public Health Service Act.
Can clofarabine be used in adult acute lymphoblastic leukemia?
Adult use may occur under institutional or physician-directed off-label protocols, but the FDA-approved U.S. indication is for patients aged 1 to 21 years with relapsed or refractory ALL after at least two prior regimens.
What is the biggest long-term threat to clofarabine sales?
Clinical displacement is the primary threat. Increased use of blinatumomab, inotuzumab ozogamicin, CAR-T therapy, and transplant-oriented treatment pathways can reduce reliance on cytotoxic salvage regimens even without direct generic competition.
References
- U.S. Food and Drug Administration. (2006). Clolar (clofarabine) injection prescribing information.
- Sanofi. (2023). Universal registration document and annual financial report 2023.
- Genzyme Corporation. (2007). Genzyme completes acquisition of Bioenvision.
- Sanofi. (2011). Sanofi completes acquisition of Genzyme.
- U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations, NDA 021673.
- U.S. Food and Drug Administration. (n.d.). Orphan drug designation and exclusivity.
